Arrowhead Pharmaceuticals posts cardiometabolic R&D webinar presentation

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

ARWR

0.00
  • Arrowhead Pharmaceuticals published a cardiometabolic R&D webinar deck outlining its RNA interference pipeline and development approach.
  • Materials highlight plozasiran, marketed as REDEMPLO, already launched for familial chylomicronemia syndrome, with expansion studies in severe hypertriglyceridemia.
  • Presentation frames additional cardiometabolic launch targets for plozasiran in severe hypertriglyceridemia in 2027, homozygous familial hypercholesterolemia in 2028.
  • Deck also profiles zodasiran, ARO-DIMER-PA, with a partnered Phase 3 Lp(a) program olpasiran being run by Amgen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.